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We performed a real-life analysis of clinical and laboratory parameters, in orally treated T2DM patients aiming at identifying
predictors of insulin treatment initiation. Overall, 366955 patients (55.8% males, age 65± 11 years, diabetes duration 7± 8 years)
were followed up between 2004 and 2011. Each patient was analyzed step-by-step until either eventually starting insulin
treatment or getting to the end of the follow-up period. Patients switching to insulin showed a worse global risk proﬁle, longer
disease duration (10± 9 years vs. 6± 7 years, respectively; p < 0 001), higher HbA1c (8.0± 1.6% vs. 7.2± 1.5%, respectively;
p < 0 001), higher triglycerides, a greater prevalence of arterial hypertension, antihypertensive, lipid-lowering and aspirin
treatment, a higher rate of nonproliferative/proliferative retinopathy, and a nearly 4 times lower prevalence of the “diet alone.”
They also showed a higher prevalence of subjects with eGFR< 60ml/min/1.73m2 (24.0% vs. 16.2%, respectively; p < 0 001).
Multivariate analysis identiﬁed diabetes duration, HbA1c, triglyceride and low HDL-C values, presence of retinopathy or renal
dysfunction, and sulphonylurea utilization (the risk being approximately 3 times greater in the latter case) as independent
predictors of insulin treatment initiation. LDL-C, lipid-lowering treatment, and overweight/obese seem to be protective. Results
of tree analysis showed that patients on sulphonylurea, with high HbA1c, eGFR below 50ml/min/1.73m2, and at least 5-year
disease duration, are at very high risk to start insulin treatment. We have to stick to this real-life picture, of course, until enough
data are collected on patients treated with innovative medications which are expected to improve beta cell survival and further
delay treatment-related insulin requirement.
1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease, charac-
terized by insulin resistance and gradual loss of beta cell
function, though the relative weight of these mechanisms
may change as disease advances [1, 2]. Due to that the answer
to “will I need insulin?,” one of the most common questions
posed to the doctor at the time of diagnosis, varies widely.
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In addition, patients with T2DM are characterized by diﬀer-
ent rates of disease progression; this often prevents them
from starting insulin treatment for many years if at all [1–4].
The United Kingdom Prospective Diabetes Study
(UKPDS) showed that beta cell functional reserve had
already halved by the time of diagnosis and continued to
decline over the following 6-year observation period on anti-
hyperglycemic therapy [5]. Nevertheless, the rate of beta cell
failure is unpredictable in the individual patient; thus, some
people with T2DM will never require insulin to treat their
blood glucose to target the desired glucose level. In fact,
lifestyle, clinical, and metabolic factors and ongoing therapies
may have a bearing on beta cell function.
The ADA guidelines [6] suggest early treatment of hyper-
glycemia in T2DM addressed to individualized targets. It
might be realized either by starting from lifestyle measures
and then adding one or more drugs stepwise at 3- to
6-month intervals until the adoption of insulin therapy or
by prescribing early insulin treatment in speciﬁc conditions.
The usual sequence of add-on treatments prior to insulin
initiation is aﬀected by many factors and is variable in speed
from person to person. With the start of insulin therapy,
some changes occur in perceived quality of life, the risk of
hypoglycemia, and/or weight gain increases and a more
stringent self-monitoring blood glucose is required, with
major eﬀects on costs, care management, and lifestyle. There-
fore, early identiﬁcation of clinical predictors of insulin treat-
ment initiation could provide clues on best possible strategies
aimed at improving the long-term management of T2DM.
Other studies already tried to engage with such an
intriguing task, but limited case series and/or the presence
of clinical factors eventually limiting the use of blood
glucose-lowering drugs other than insulin did not allow
drawing ﬁrm conclusions on this issue [7–9]. Renal function,
as expressed by glomerular ﬁltration rate (GFR), progres-
sively decreases with time and is expected to be one of the
most relevant factors leading to insulin therapy [10].
We therefore took advantage of the large AMD Annals
initiative database [11] to perform a real-life analysis of
clinical and laboratory parameters, complications, and pat-
terns of glucose-lowering treatment in noninsulin-requiring
T2DM patients with the aim of correlating to age and base-
line renal function, the pattern of insulin treatment initiation
eventually occurring during follow-up.
2. Materials and Methods
2.1. Study Design, Study Patients, and Data Sources. In the
present report, we analyze a large series of patients with
T2DM followed up by 301 diabetes centers (DC) homoge-
neously distributed throughout the country among those
aﬃliated to the Italian Association of Clinical Diabetologists
(AMD) initiative with the aim of investigating possible
predictors of future insulin treatment initiation according
to age and kidney function. From the databases pertaining
to those 301 DCs, 510182 people with T2DM were selected
at their ﬁrst estimated GFR (eGFR) evaluation, but immedi-
ately after, those already on insulin (n = 141832) or less than
18 years old (n = 39) or assisted by DCs with <100 patients
were excluded to minimize selection bias. So, in the end,
366955 noninsulin-treated T2DM patients followed up
by 267 DCs entered the study (ﬂow chart, Supplementary
Figure 1). The analysis was performed using the data
set of electronic medical records collected between 2004
and 2011.
2.2. Data Collection. As already reported, the analysis of the
database is an ongoing Italian AMD Annals initiative aimed
at identifying a set of indicators to be used and consistently
ﬁne-tuned in the context of continuous quality improve-
ment. Participating DCs adopted the same computer pro-
gram for the everyday management of outpatients, while a
dedicated software package allowed us to extract and analyze
needed information from the database (AMD data ﬁle). The
latter in fact collected information exclusively from patients
who preliminarily signed their informed consent to the
anonymous utilization of their own data for clinical evalua-
tions targeted at diabetes community health and quality of
life improvement.
The results were internally approved by the AMDAnnals
scientiﬁc committee. The diagnosis of type 2 diabetes was
made/conﬁrmed at each participating DC according to
criteria deﬁned by the ADA Standards of Medical Care in
Diabetes 2014 [6]. The International Classiﬁcation of Dis-
eases, Clinical Modiﬁcation (ICD-9-CM, V82.9 2014) was
used to deﬁne T2DM diagnosis and comorbidities and/or
complications [12].
The AMD Annals Initiative included measuring and reg-
ularly recording HbA1c, blood pressure (BP), low-density
lipoprotein cholesterol (LDL-c), total and high-density
lipoprotein cholesterol (TC and HDL-c, respectively), tri-
glycerides (TG), and serum uric acid (SUA) by high standard
autoanalyzers in public laboratories successfully participat-
ing in nationwide quality control programs. The use of
speciﬁc classes of drugs (metformin, other antihyperglycemic
agents (AHA), statins, and antihypertensive drugs) was also
evaluated. Kidney function was assessed by serum creati-
nine and urinary albumin excretion measurements. eGFR
was calculated for each patient using a standardized serum
creatinine assay and the CKD-EPI equation [13].
To be included in the study, each patient had to pro-
vide at least one measurement of serum creatinine, with
concordant eGFR values, in the 3 months prior to study
entry. Increased urinary albumin excretion (UAE) was
diagnosed as (i) microalbuminuria if urinary albumin con-
centration was >30 and ≤300mg/l or if UAE rate was >20
and ≤200μg/min or if urinary albumin-to-creatinine ratio
(ACR) was >2.5mg/mmol in men and >3.5mg/mmol in
women and ≤30mg/mmol in both genders and (ii) macroal-
buminuria if urinary albumin concentration was >300mg/l
or if UAE rate was >200μg/min or if ACR was >30mg/mmol
in both genders. Albuminuria indicated patients with either
micro- or macroalbuminuria.
Each enrolled patient entering the study was analyzed
step-by-step until either eventually starting insulin treatment
or getting to the end of the follow-up period. Six months was
the input cut-oﬀ in the study, so that the follow-up period
ranged from 6 to 96 months, the latter being the case for
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patients joining already in 2004 and keeping there until 2011
(8 years). As this survey was realized under real-life condi-
tions, a variable amount of missing data occurred for each
patient at any steps of the follow-up; the sample size contrib-
uting to every follow-up step is given systematically in all
result tables.
2.3. Statistical Analysis. Data are shown as mean values±
standard deviation. Categorical variables are given as fre-
quencies and percentages. Comparisons were performed
by mixed models with clinics ﬁtted as random eﬀect to
take into account possible diﬀerences across centers. Time
to insulin treatment analysis was performed by means of
the Cox proportional hazard model with stratiﬁcation by
DCs. Several multivariate models, including an incremen-
tal number of variables over subgroups of patients with
all data available, were performed to take into account
the diﬀerent completeness of patients’ features. Hazard
ratios (HRs) were provided for each baseline characteristic.
In details, model 1 was based on a limited number of fac-
tors over most of the patients. Models 2 to 4 introduced
other risk factors, but the sample size decreased. The full
model 4 had 44.611 patients in comparison to model 1
that included 323.769 patients. Variables were categorized
by clinical cut-point values. p values< 0.05 were taken as
statistically signiﬁcant. The cumulative incidence curves
for insulin treatment were based on Kaplan–Meier analysis.
To deﬁne a hierarchical event risk tree, the Cox proportional
hazard model was utilized for insulin therapy initiation to
recursively split the data into diﬀerent subgroups by select-
ing variables characterized by the least p values. Continu-
ous variables were analyzed for all values ranging 5th to
95th percentile by selecting the best cut-point with the
lowest p value. The tree-building process was stopped after
three iterations yielding eight groups. All analyses were
performed using STATA software, version 14 (Stata-Corp
LP, College Station, TX).
3. Results
Three hundred and sixty-ﬁve thousand nine hundred and
ﬁfty-ﬁve individuals with T2DM from two hundred and
sixty-seven DCs were evaluated. Overall, 54220 patients
started insulin therapy at follow-up. Cumulative incidence
of insulin treatment initiation was as follows: 1 year 2.5%,
2 years 6.1%, 3 years 10.3%, 4 years 14.5%, 5 years 19.6%,
6 years 24.7%, 7 years 30.1%, and 8 years 36.3%.
The median follow-up with interquartile range was 42
months (21–67), reﬂecting the fact that half of the patients
were followed up for at least 42 months, 25% for 21 months,
and 75% for 67 months, respectively.
3.1. Baseline Clinical Characteristics of the Whole Population
and Stratiﬁed by Insulin Treatment during Follow-up. Clini-
cal features of the whole study sample are reported in
Table 1. Overall, entry age was 65± 11 years, diabetes
duration was 7± 8 years, BMI was 30± 5 kg/m2, and 55.8%
patients were males. Glycemic control, lipid parameters, and
BP levels were fairly good, with mean HbA1c, LDL-C, and
systolic/diastolic BP values of 7.3± 1.6%, 118± 36mg/dl,
and 140± 19/81± 10mmHg, respectively. Mean eGFR was
78± 19ml/min/1.73m2. 5.3% and 1.2% people had non-
proliferative and proliferative retinopathy, respectively;
38.3% were on lipid-lowering agents (34.7% on statins
and 2.3% on ﬁbrates), 58.4% on antihypertensive treat-
ment, and 16.6% on aspirin. As for glycemic control,
11.5% patients were on diet alone (n = 42056), 27.2% on
metformin (n = 99718), 43.5% onmetformin+ sulphonylurea
(n = 159664), 17% on sulphonylurea alone (n = 62276), and
0.9% on pioglitazone (n = 3241). Due the time course of the
study—starting at the very beginning of incretin utilization
and closing before SGLT2 inhibitor availability—only a
minority of patients were taking incretins and no one was
on SGLT2 inhibitors.
Table 1 also summarizes baseline clinical characteristics
of the 54220 patients (15% of the studied population) who
were treated with insulin by the end of follow-up versus their
noninsulin-treated counterpart. Patients in the former group
showed a worse global risk proﬁle and, despite a higher prev-
alence of subjects with eGFR< 60ml/min/1.73m2 (24.0%
vs. 16.2%, respectively; p < 0 001), were more likely to receive
a prescription for sulphonylurea, either alone (19.4% vs.
16.5%, respectively; p < 0 001) or in association with metfor-
min (65.7% vs. 39.7%, respectively; p < 0 001). As clearly
shown in the table, the subgroup of patients treated with
insulin also showed longer disease duration (10± 9 years
vs. 6± 7 years, respectively; p < 0 001), higher HbA1c
(8.0± 1.6% vs. 7.2± 1.5%, respectively; p < 0 001), higher
triglycerides (both in terms of mean values and of percentage
of subjects with values> 150mg/dl), a greater prevalence of
arterial hypertension, and a higher rate of nonproliferative/
proliferative retinopathy. The insulin-treated group also dis-
played a signiﬁcantly higher prevalence of concomitant anti-
hypertensive, lipid-lowering and aspirin treatment, and a
nearly 4 times lower prevalence of the “diet alone” approach.
Clinical baseline characteristics are reported in Sup-
plementary Table 1. Patients were stratiﬁed according to
follow-up duration until insulin treatment started. A clear
relationship between overall cardiovascular and metabolic
risk proﬁle and time to insulin treatment is evident; a worse
baseline proﬁle is associated with a shorter follow-up before
switching to insulin. People on pioglitazone or metformin
alone, as well as those with elevated uric acid levels or
antihypertensive treatment, were unlikely to receive insulin
treatment at follow-up.
3.2. Multivariate Cox Regression Analysis for Insulin
Treatment during Follow-up. Table 2 displays the results of
the multivariate Cox regression analysis for insulin treatment
during follow-up according to four diﬀerent models ordered
by increasing data completeness. A relatively small sample
(n = 44611) eventually contributed to the complete model,
which identiﬁed all variables signiﬁcantly and independently
associated to insulin treatment initiation, including known
diabetes duration (rather than age per se), HbA1c, triglycer-
ide and low HDL-C values, and the presence of retinopathy
or renal dysfunction (reduced eGFR or the presence of
micro-/macroalbuminuria). On the other hand, LDL-C and
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lipid-lowering treatment were associated with a greater
chance of not initiating insulin treatment over the study
period. Overweight and obese status also seem to decrease
the risk. Moreover, as for hypoglycemic agent utilization,
when diet-treated subjects are taken as the reference
group, the risk of switching to insulin was 2.8 to 3.6 times
greater for people on sulphonylurea (alone or combined
with metformin, respectively).
Table 1: Baseline clinical characteristics of whole population and grouped by insulin treatment at follow-up.
All No insulin Insulin
p
n = 366955 n = 312735 n = 54220
Male sex 204940 (55.8%) 175240 (56.0%) 29700 (54.8%) <0.001
Age (years) 65± 11 65± 11 66± 11 <0.001
Duration of diabetes (years) 7± 8 6± 7 10± 9 <0.001
BMI (kg/m2) 30± 5 30± 5 29± 5 <0.001
Waist circumference (cm) 103± 13 103± 12 103± 13 0.205
Serum creatinine (mg/dl) 0.95± 0.53 0.95± 0.52 1.00± 0.60 <0.001
eGFR (ml/min/1.73m2) 78± 19 79± 19 75± 21 <0.001
eGFR< 60ml/min/1.73m2 63635 (17.3%) 50620 (16.2%) 13015 (24.0%) <0.001
Albuminuria 31814 (21.1%) 25661 (20.1%) 6153 (27.4%) <0.001
Microalbuminuria 27125 (18.0%) 22125 (17.3%) 5000 (22.2%) <0.001
Macroalbuminuria 4689 (3.1%) 3536 (2.8%) 1153 (5.1%) <0.001
Serum uric acid (mg/dl) 5.5± 1.9 5.5± 1.9 5.4± 1.8 <0.001
Serum uric acid in the quintile 31171 (18.9%) 26503 (18.8%) 4668 (19.0%) <0.001
HbA1c (%) 7.3± 1.6 7.2± 1.5 8.0± 1.6 <0.001
HbA1c≥ 7% 179176 (50.2%) 140643 (46.2%) 38533 (72.9%) <0.001
Total cholesterol (mg/dl) 198± 43 198± 42 198± 43 <0.001
Triglycerides (mg/dl) 156± 121 154± 118 166± 139 <0.001
Triglycerides≥ 150mg/dl 126931 (38.7%) 106597 (38.0%) 20334 (42.9%) <0.001
HDL (mg/dl) 50± 14 50± 14 50± 14 <0.001
HDL< 40mg/dl (M), <50mg/dl (F) 108975 (34.0%) 92748 (33.8%) 16227 (35.0%) <0.001
LDL (mg/dl) 118± 36 119± 36 117± 36 <0.001
LDL≥ 100mg/dl 216751 (68.6%) 186353 (68.9%) 30398 (67.0%) <0.001
Systolic BP (mmHg) 140± 19 140± 19 142± 20 <0.001
Diastolic BP (mmHg) 81± 10 81± 10 81± 10 <0.001
BP≥ 140/85mmHg 192966 (62.4%) 163268 (61.9%) 29698 (64.9%) <0.001
Nonproliferative retinopathy 19410 (5.3%) 14516 (4.6%) 4894 (9.0%) <0.001
Proliferative retinopathy 4479 (1.2%) 3183 (1.0%) 1296 (2.4%) <0.001
Smokers 33276 (17.2%) 28479 (17.1%) 4797 (18.2%) <0.001
Lipid-lowering treatment 140692 (38.3%) 121976 (39.0%) 18716 (34.5%) <0.001
Treatment with statins 127489 (34.7%) 110893 (35.5%) 16596 (30.6%) <0.001
Treatment with ﬁbrates 8399 (2.3%) 6985 (2.2%) 1414 (2.6%) <0.001
Antihypertensive treatment 214395 (58.4%) 182658 (58.4%) 31737 (58.5%) 0.003
Treatment with ACE-Is/ARBs 177232 (48.3%) 150950 (48.3%) 26282 (48.5%) 0.003
Aspirin 60816 (16.6%) 51548 (16.5%) 9268 (17.1%) <0.001
Diet 42056 (11.5%) 40220 (12.9%) 1836 (3.4%) <0.001
Biguanides and sulphonylureas 159664 (43.5%) 124017 (39.7%) 35647 (65.7%) —
Biguanides 99718 (27.2%) 93745 (30.0%) 5973 (11.0%) <0.001
Sulphonylureas 62276 (17.0%) 51751 (16.5%) 10525 (19.4%) <0.001
Glitazones 3241 (0.9%) 3002 (1.0%) 239 (0.4%) <0.001
Mean ± SD or absolute frequency (percentage). ACE-Is: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor antagonists; ALT: alanine
transaminase; AST: aspartate aminotransferase; BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular ﬁltration rate; GGT: gamma-
glutamyltransferase; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol. Serum uric acid
gender speciﬁc quintile: females > 6.3 mg/dl and males > 6.8 mg/dl. Patients’ baseline missing data: duration of diabetes 34769 (9.5%), BMI 42789 (11.7%),
waist circumference 281370 (76.7%), albuminuria 216481 (59.0%), serum uric acid 201675 (55.0%), HbA1c 9865 (2.7%), total cholesterol 35355 (9.6%),
triglycerides 38722 (10.6%), HDL 46234 (12.6%), LDL 51112 (13.9%), systolic and diastolic BP (mmHg) 57478 (15.7%), and smoking status 173783 (47.4%).
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3.3. Use of Statin Seems to Protect From Insulin Treatment
Initiation. The incidence of insulin treatment initiation dur-
ing follow-up, on the basis of the type of initial therapeutic
(glucose-lowering) treatment, is described in Supplementary
Figure 2. As already said, the risk was much higher in case of
sulphonylurea, either alone or in association with metformin,
while it remained rather low and almost stable over time in
patients on diet or glitazones or metformin alone.
Baseline mean± SD values or absolute rates (percentage)
of all the investigated parameters are also reported on the
basis of hypoglycemic treatment. From this point of view,
many patients with eGFR< 60ml/min/1.73m2 were on sul-
phonylurea alone (n. 18983; 30.5%) or associated with
metformin (n. 26465; 16.6%), while only 446 of 1806 (13.8)
were under pioglitazone (Supplementary Table 2).
The cumulative incidence of insulin treatment initiation
during follow-up was greater in patients with eGFR< 60ml/
min/1.73m2 at baseline in comparison to those with 60–
90 or >90 which had a similar incidence (Supplementary
Figure 3).
In Figure 1, the mean changes from baseline (%) (±SD)
are shown for all parameters found to be signiﬁcant by mul-
tivariate analysis. All of them were signiﬁcantly worse at the
end of follow-up in insulin-treated patients (p < 0 001).
Finally, by applying a tree analysis model, we identi-
ﬁed eight patient subgroups at diﬀerent risks for starting
insulin treatment during follow-up; the strongest variable
in terms of risk diﬀerentiation was sulfonylurea utiliza-
tion. In fact, the lowest risk for starting insulin treat-
ment was found in patients on other drugs and with
HbA1c≤ 7.1% and eGFR≥ 50ml/min/1.73m2 at baseline.
When taking them as a reference (class #8), the incidence
of insulin initiation progressively increased across classes
down to #1, which was mostly including patients on sul-
phonylurea, with HbA1c> 7.5% and disease duration> 5
years (Figure 2).
Table 2: Multivariate Cox regression analyses for insulin treatment at follow-up.
Patients with complete data
Model 1 Model 2 Model 3 Model 4
N = 323769 N = 236412 N = 73069 N = 44611
Hazard ratio p Hazard ratio p Hazard ratio p Hazard ratio p
Male sex 1.037 <0.001 1.035 0.002 0.993 0.724 0.985 0.587
Age (by 10 years) 0.955 <0.001 0.958 <0.001 0.970 0.014 0.970 0.052
Duration of diabetes (by 10 years) 1.315 <0.001 1.332 <0.001 1.350 <0.001 1.363 <0.001
HbA1c (by 1%) 1.264 <0.001 1.260 <0.001 1.243 <0.001 1.241 <0.001
Nonproliferative retinopathy 1.287 <0.001 1.288 <0.001 1.256 <0.001 1.277 <0.001
Proliferative retinopathy 1.436 <0.001 1.392 <0.001 1.441 <0.001 1.547 <0.001
eGFR below 90 (by 10ml/min/1.73m2) 1.157 <0.001 1.139 <0.001 1.122 <0.001 1.121 <0.001
Triglycerides≥ 150mg/dl 1.079 <0.001 1.060 0.007 1.095 0.001
HDL< 40mg/dl (M), <50mg/dl (F) 1.100 <0.001 1.103 <0.001 1.124 <0.001
LDL≥ 100mg/dl 0.819 <0.001 0.863 <0.001 0.861 <0.001
Systolic/diastolic BP≥ 140/85mmHg 0.950 <0.001 0.945 0.009 0.949 0.059
Albuminuria
Normoalbuminuria Reference Reference
Microalbuminuria 1.366 <0.001 1.414 <0.001
Macroalbuminuria 2.028 <0.001 2.210 <0.001
BMI
<27 kg/m2 Reference
27–30 kg/m2 0.882 <0.001
>30 kg/m2 0.834 <0.001
Serum uric acid in the top quintile 1.046 0.209
Lipid-lowering treatment 0.912 <0.001 0.901 <0.001 0.867 <0.001 0.855 <0.001
Antihypertensive treatment 1.002 0.819 0.999 0.916 1.000 0.998 1.020 0.501
Aspirin 1.007 0.598 1.010 0.515 1.002 0.948 1.002 0.966
Antidiabetic treatment
Diet Reference Reference Reference Reference
Biguanides and sulphonylureas 3.860 <0.001 3.963 <0.001 3.581 <0.001 3.511 <0.001
Sulphonylureas 2.874 <0.001 2.950 <0.001 2.806 <0.001 2.804 <0.001
Glitazones 1.649 <0.001 1.691 <0.001 1.469 0.011 1.534 0.031
Biguanides 1.286 <0.001 1.283 <0.001 1.188 0.004 1.209 0.012
Hazard ratios from multivariate Cox proportional hazard models for insulin treatment during follow-up.
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4. Discussion
In this report, we describe the risk proﬁle for insulin treat-
ment initiation in real-life conditions in a large population
of patients with T2DM attending diabetes centers in Italy
with an average follow-up of 42 months (21–67) and accord-
ing to age and kidney function. Our data show a cumulative
incidence of insulin treatment initiation on 5-year follow-up
of 15%.
The ADA guidelines [6] suggest hyperglycemia to be
treated as early as possible, even with insulin in speciﬁc cases,
to address T2DM individualized targets. However, perceived
quality of life deteriorates and major eﬀects on costs, organi-
zation of care, and lifestyle occur after insulin enters patients’
treatment regimen. For these reasons, it is important to iden-
tify early parameters predicting insulin treatment initiation.
Other previously performed real-life studies sought an
answer to this question as well, but unfortunately, they
involved a small series of patients, analyzed diﬀerent care
settings, and took only a few parameters into consideration.
In the Netherlands study, the cumulative incidence of the
need for an insulin switch was 36% over a 4–5-year period
[14]. After nine years of follow-up in the United Kingdom
Prospective Diabetes Study (UKPDS), 30% patients had
switched to insulin treatment [15]. In another study, insulin
therapy was started in 29.7% patients over a 2-year period
[16]. In a population-based cohort study among elderly
persons in Quebec, the insulin switch rate was 9.7 cases per
1000 patient-years [17], which appears very low. In the
Sweden study, 25% patients with type 2 diabetes had insulin
prescribed within 6 years of starting oral hypoglycemic
agents and this ﬁgure rose to 42% within 10 years, corre-
sponding to an annual rate of insulin initiation of 4% [8].
In the Australian Fremantle Diabetes Study, 15% patients
had switched to insulin treatment within 5 years of follow-
up [18]. The retrospective Scottish study estimated that
5.8% of those on oral hypoglycemic agents would start insu-
lin each subsequent year within a median of 1.6 years [19].
The rate of insulin initiation described in various studies
appears to be rather heterogeneous. In our opinion, this
aspect can be related to the huge diﬀerences among related
publications in terms of patient selection criteria, study
parameters (clinical/biochemical variables, complications,
and comorbidities), care settings, developing [6] or devel-
oped country daily practice habits, patient education, and
quality of care of diﬀerent health systems. On the contrary,
in our view, it is vital to identify early predictors of insulin
start: known duration of diabetes, low HDL-cholesterol, high
HbA1c, BMI, triglycerides, and LDL-cholesterol values, as
well as lipid-lowering treatment, eGFR, and retinopathy. A
previous use of sulphonylurea, either alone or even more
strongly when combined with metformin, was also found to
predict the initiation of insulin therapy. The strong associa-
tion of use of these drugs with the initiation of insulin treat-
ment could be interpreted as a marker of a more complex
disease and/or a loss of beta cell function with time, although
a causative role cannot be excluded.
It is known that sulphonylureas act by activating insulin
release from the pancreatic beta cell. However, with long-
term use, there is a progressive decrease in their eﬀectiveness.
This loss of eﬀect is in part due to a reduction in insulin-
producing capacity by the pancreatic beta cell, as shown by
the UKPDS study [20]. In addition, among several hypo-
glycemic drugs which may inﬂuence beta cell function,
secretagogues appear to be the most prone to failure [4].
In fact, sulfonylurea-mediated hyperexcitation of beta cell
may trigger excitotoxic reactions leading to increased rates
of beta cell apoptosis [21]. As a result, beta cell mass
decreases, and this is seen as the major cause of the devel-
oping insulin deﬁciency [22]. Consequently, control of
hyperglycemia is transitory with sulphonylureas and no
durable eﬀect on HbA1c is observed.
Although experimental randomized prospective studies
show that insulin therapy can be safe and eﬃcacious in
improving glycemic control in T2DM [15, 23, 24], little is
known about factors associated with switching from nonin-
sulin to insulin therapy in routine practice. Goddijn prospec-
tively studied a cohort of patients with T2DM referred by
general practitioners to an outpatient department for consid-
eration for insulin therapy. They found that, similarly to our
ﬁnding, switchers had a higher HbA1c and a lower BMI [25].
Ringborg et al. also performed a retrospective study on a
population-based cohort of patients with T2DM within the
Swedish RECAP-DM study for the initiation of insulin
therapy. They also found that switchers had a higher HbA1c
[8]. Spoelstra et al. [14] also found a higher HbA1c in
patients initiating insulin therapy. Younger age and female
gender were suggested by some researchers [19, 26] as factors
associated with insulin initiation but could not be conﬁrmed
by others [17] including ourselves; this warrants further
investigation. The high HbA1c levels at the beginning of
insulin therapy may also be seen as a sign of therapeutic
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Figure 1: Change (%) from baseline by insulin treatment of main
signiﬁcant parameters identiﬁed by multivariate analysis. All
diﬀerences were statistically signiﬁcant (p < 0 001). Patients with
less than one-year follow-up duration were excluded. Numbers of
paired observations at baseline and ﬁnal visits were: BMI 193238,
HbA1c 227368, eGFR 183858, Triglycerides 171670, HDL-C
164966, LDL-C 160112, respectively.
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inertia, since all over the world, as demonstrated by the
TREAT study, insulin therapy is usually started only at very
high HbA1c levels [27].
Among measured biochemical factors, higher triglyceride
levels were found to be associated with long-term oral
hyperglycemic agent failure, and in our hands, Cox regres-
sion conﬁrmed triglycerides to be a strong predictor for
future insulin requirement. This is a major point, because
hypertriglyceridemia may serve as a marker of reduced insu-
lin production or activity and may indicate the presence of
lipotoxicity, which can lead to beta cell loss [28], especially
in the presence of hyperglycemia [29].
In our sample, use of statins seems to protect from
insulin therapy initiation. This data is in accord with Yee
et al. who found in a large cohort including 10996 T2DM
patients, new users of oral antidiabetic agents, that use of
statins was associated with a delay in starting insulin treat-
ment [30]. Although the role of statins in modulating the
risk of diabetes onset is still debated, Freeman et al. have
reported that use of pravastatin was associated with
decrease of diabetes development postulating that the
anti-inﬂammatory actions of statins might decrease the
proinﬂammatory milieu that predisposes to insulin resis-
tance and diabetes [31]. It seems plausible that the same
mechanisms of action would operate in patients with estab-
lished diabetes and lead to a delay in the need for starting
insulin treatment.
In contrast with our results, previous data suggest that
eGFR decline is a signiﬁcant predictor of insulin treatment
start in patients treated with metformin, but not in those
receiving sulphonylurea in general practice. This may depend
on the limited number of patients studied by Kostev et al.
[10] as well as on a diﬀerent care setting. In fact, in Germany,
general practitioners use metformin less extensively and
recur to insulin earlier than in Italy. Culturally driven
diﬀerences in therapeutic attitudes in diﬀerent countries
may justify the observed heterogeneity among studies’
results. Thus, for example, in a recently published report
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Figure 2: Hierarchical tree of insulin treatment initiation risk during follow-up.
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from the AMDAnnals initiative in Italy, a large proportion of
patients with T2D were still receiving metformin despite
eGFR values< 30ml/min/1.73m2[32].
Moreover, yearly incidence of insulin switch might
erroneously suggest a naturally occurring, somewhat age-
dependent, eﬀect. This is not the case, as the statistics
behind reﬂects a “time-to-event” or survival analysis where
estimated absolute risk increases with the increase of the
time interval. In greater detail, yearly incidence of insulin
treatment initiation did not depend on the length of
follow-up per se because each patient was analyzed until
the end of his own time oﬀ insulin and exited the group
thereafter. For example, a patient with 2-year follow-up
was analyzed only up to the 2nd year and was excluded
from subsequent analysis.
The tree analysis allowed us to investigate also the
interaction between several clinical variables and their
hierarchical impact on insulin treatment initiation and
proved useful to provide physicians with clinically rele-
vant hints. The results of this analysis clearly show that
patients on sulphonylurea with high HbA1c, eGFR below
50ml/min/1.73m2, and diabetes duration longer than 5
years are at very high risk to start insulin treatment
during follow-up.
We believe in the high value of identifying predictors
of insulin treatment. This valuable information will allow
clinicians and patients to apply preventive strategies and
operate aiming to postpone an insulin therapy approach.
Our study has some limitations. First of all, data
regarding the entire 5-year follow-up period (ranging from
6 to 96 months) were available for most but not all patients
because this survey was realized under real-life conditions
and a variable amount of missing data occurred for each
patient at any steps of the follow-up. Nevertheless, we believe
that this may have been counterbalanced by the very large
sample size of our study. Furthermore, our data may not be
applicable to the population of patients with T2DM at large,
as the vast majority of participants were of white origin.
Ethnicity has previously been shown to bear some impact
on the risk of developing renal complications [33]. Finally,
recorded therapeutic regimens largely reﬂect clinical practice
attitudes during the time period of our study, which starts at
the very beginning of incretin utilization and closes oﬀ just
before SGLT2 inhibitor availability. As a consequence, only
a minority of patients were taking incretins and none was
on SGLT2 inhibitors.
However, we should mention the large size of the
study cohort and the homogeneous geographical distri-
bution of the recruiting centers as well as the relatively
long follow-up period, which once again contribute in
making the study cohort a good representation of real-life
clinical practice.
5. Conclusions
In conclusion, even if patients with T2DM are characterized
by diﬀerent rates of disease progression and the clinical
presentation of the disease could lead to insulin treatment
initiation per se, the analysis of the collected data allows us
to partly respond to typical patient’s question “will I need
insulin?,” which originated in this paper. Multivariate analy-
sis identiﬁed several signiﬁcant predictors of insulin treat-
ment initiation: diabetes duration, HbA1c, triglyceride and
low HDL-C values, the presence of retinopathy or renal func-
tion deterioration, and sulphonylurea utilization (the risk
being approximately 3 times up greater in the latter case).
Opposite to that, LDL-C, lipid-lowering treatment, and
normal weight/overweight seemed to be protective.
Notably, the tree analysis sheds light upon the inter-
action between those variables and thus deﬁned the hier-
archical impact of these variables on insulin treatment
initiation, identifying T2DM patients on sulphonylurea,
with high HbA1c, eGFR below 50ml/min/1.73m2, and at
least 5 years of disease duration as those at very high risk
to start insulin treatment.
We have to stick to this real-life picture, of course,
until enough data are collected from patients treated with
innovative medications which are expected to improve
beta cell survival and further delay treatment-related insu-
lin requirement.
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